



**Figure S1** The study design diagram. NSCLC, non-small cell lung cancer; *EGFR*, epidermal growth factor receptor; QD, once daily; QOD, every other day; ORR, objective response rate; DCR, disease control rate; OS, overall survival; PFS, progression-free survival.

**Table S1** Subject characteristics

Characteristics	Number (n=11)	Percentage (%)
Age (years)		
Median	68	
Range	47–73	
Gender		
Male	4	36.4
Female	7	63.6
Smoking status		
Never	9	81.8
Prior/current	2	18.2
Histology		
Squamous	0	0.0
Non-squamous	11	100.0
<i>EGFR</i> mutation		
<i>Exon 19 deletion</i>	5	45.5
<i>Exon 21 L858R</i>	6	54.5
CNS metastases		
Yes	9	81.8
No	2	18.2
ECOG		
0–1	4	36.4
≥2	7	63.6
EGFR-TKI choice		
Osimertinib	9	81.8
Aumolertinib	2	18.2

*EGFR*, epidermal growth factor receptor; CNS, central nerve system; ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor.

**Table S2** trAEs

AE term	Any trAE (n=9), n (%)	trAE grade 3–5 (n=9), n (%)
Skin disorders		
Rash	2 (22.2)	1 (11.1)*
Respiratory disorders		
Interstitial pneumonia	1 (11.1)	1 (11.1)*
Gastrointestinal disorders		
Diarrhea	1 (11.1)*	0 (0.0)
Stomachache	1 (11.1)*	1 (11.1)*
Vascular disorders		
Pulmonary embolism	1 (11.1)	1 (11.1)*
Metabolism disorders		
Hyponatremia	1 (11.1)	1 (11.1)*

Of note, there were no grade 5 trAEs observed on trial. \*, led to the subject's discontinuation of the trial. trAE, treatment-related adverse event; AE, adverse event.